Earlier this week, we shared our second Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Researchers reviewed research into the medical and toxicological viewpoints of tattooing the skin from the past decade.

A recent study spotlights an opportunity for interdisciplinary collaboration between dermatologists and orthodontists.

VELA is the first phase 3 hidradenitis suppurativa trial to evaluate HiSCR75 as the primary end point.

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Acinonyx Bio's topical cream, ACX, targets Propionibacterium acnes.

The results are both confirmatory and extend the response results from a prior phase 3 trial known as FLASH.

Clinicians, especially those who see patients with inflammatory and pigmentary disorders, should incorporate alcohol use disorder screening measures into all patient visits.

In this month’s Cosmetic Conundrums column, explore what dermatology clinicians need to know about false eyelashes to help prevent infections or contact dermatitis.

Researchers have developed a clinical decision support model using machine learning to assist health care providers in predicting diagnoses of hidradenitis suppurativa.

These results are indicative of the need for dermatologists to discuss social media misinformation and low quality information with their patients.

Researchers say addressing socioeconomic differences may be the key to addressing this disparity.

Dermatology PAs and NPs continue to address the demand-supply mismatch in dermatologic care and can significantly bring their skills within the primary care model.

The needs assessment surveyed patients’ stage of treatment, radiation-induced dermatologic adverse effects, and over-the-counter products and home remedies that were used.

Researchers found that abrocitinib demonstrated rapid, sustained, and deep improvements in several important domains of itch-dominant AD.

In a comparison of pediatric dermatologists versus AI, dermatologists primarily exhibited greater performance.

Mark Lebwohl, MD, and Saakshi Khattri, MD, discuss the evolving landscape of plaque psoriasis treatments over the past year.

The analysis revealed a higher rate of discontinuations due to immune-mediated adverse experiences.

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.

Muscle spasms are the most common adverse event experienced by patients treated with hedgehog inhibitors for basal cell carcinomas.

This week’s collection of the latest dermatologic studies includes artificial intelligence in cutaneous lesions, dupilumab-induced acanthosis nigricans, aesthetic considerations for treating lesbian, gay, and bisexual patients, and monotherapies for male androgenetic alopecia.

This Skin Cancer Awareness Month, take a look at previous coverage from 2024.

They are confident prescribing roflumilast to patients with diverse skin and hair characteristics, including those with a history of hair treatments.

5 experts share insights on long-term safety, efficacy, demographic variances, and more in pediatric AD.